FDA queries drug-coated stent trial protocols
This article was originally published in Clinica
Biocompatibles International and Boston Scientific are anticipating slight delays in starting their respective drug-coated stent trials in the US, after the US FDA requested further information in response to the firms' investigational device exemption (IDE) submissions.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.